Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib in Relapsed/Refractory CLL/SLL
NCT03206918Phase 2Completed
- Sponsor
- BeiGene
- Start
- Mar 2017
- Primary completion
- Jun 2018
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by BeiGene. Primary endpoint: Overall Response Rate. Started Mar 2017; status: completed.
02
Drugs
zanubrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03206918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206918.